Giant malignant gastrointestinal stromal tumors: Recurrence and effects of treatment with STI-571

Table 1 Clinical characteristics of giant GISTs patients.

	Total (n = 23)	STI-571 (n = 9)	No STI-571 (n = 14)	P
Age (yr)	56.2±16.9
≤50 yr		40.2±11.9(5)	39.0±10.8(4)	0.8
>50 yr		67.3±5.8(4)	66.7±11.0(10)	0.9
Sex
Male	11	2	9	0.08
Female	12	7	5
Tumor size (cm)	15.9±8.4	20.7±9.9	12.8±5.4	0.06
Location
Gastroduodenal	14	6	8	0.9
Intestinal	9	3	6
Surgical margin
Negative	12	4	8	0.68
Positive	11	5	6
Recurrence	14	7	7
Local	11	5	6	0.59
Distal metastasis	6	4	2
Treatment of recurrence	14	7	7
Repeat resection	3	3	0
TACE	2	2	0
Chemotherapy	3	2	2
Mean recurrence time (mo)		15.2±11.8	6.9±5.7	0.15

TACE = Trans-arterial chemo-embolization.

Table 2 Effects and side effects of STI-571.

	Number (n = 9)
Tumor shrinkage	6
Complete response	2
Tumor shrinkage ≥75%	0
50% <Tumor shrinkage <75%	3
25% <Tumor shrinkage <50%	1
Tumor shrinkage ≤25%	2
Tumor enlargement (150%)	1
Tumor re-enlargement (150%)	1
Side effect	8
Skin rash	4
Edema	5
Gastrointestinal upset	1
Disease progress	1
Abnormal liver function	1

Table 3 Prognostic variables for survival analysis.

Variable	Mortality (n = 8)	Log-rank test
Age (yr)		0.085
≤50 yr	1/9
>50 yr	7/14
Sex
Male	4/11	0.95
Female	4/12
Location		0.872
Gastroduodenal	5/14
Intestinal	3/9
Surgical margin		0.047
Negative	2/12
Positive	6/11
STI-571		0.045
Yes	1/9